Regulatory considerations for the development of autologous induced pluripotent stem cell therapies

Regenerative Medicine

Volumn 5, Issue 4, 2010, Pages 569-579

  Carpenter, Melissa K ^a   Couture, Larry A ^a  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

autologous cell therapy; cell replacement therapy; induced pluripotent; safety; stem cell

Indexed keywords

CRE RECOMBINASE; KRUPPEL LIKE FACTOR 4; MYC PROTEIN; OCTAMER TRANSCRIPTION FACTOR 4; TRANSCRIPTION FACTOR SOX2;

AUTOLOGOUS STEM CELL TRANSPLANTATION; CELL DIFFERENTIATION; CELL EXPANSION; CELL LINEAGE; CELL POPULATION; CELL REGENERATION; CYTOGENETICS; DNA MODIFICATION; EMBRYONIC STEM CELL; EPIGENETICS; GENETIC STABILITY; GENETIC VARIABILITY; HUMAN; IMMUNOMODULATION; KERATINOCYTE; LIVER CELL; PLURIPOTENT STEM CELL; PRIORITY JOURNAL; PROTEIN ENGINEERING; REGENERATIVE MEDICINE; REPRODUCIBILITY; REVIEW; SAFETY; SOMATIC MUTATION; TERATOMA;

DRUG INDUSTRY; GUIDELINES AS TOPIC; HEALTH POLICY; HUMANS; INDUCED PLURIPOTENT STEM CELLS; TISSUE ENGINEERING; TISSUE THERAPY; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 77954788920     PISSN: 17460751     EISSN: None     Source Type: Journal    
DOI: 10.2217/rme.10.55     Document Type: Review

References (51)

1. Yu J, Thomson JA: Pluripotent stem cell lines. Genes Dev. 22(15), 1987-1997 (2008).
2. Thomson JA, Itskovitz-Eldor J, Shapiro SS, et al.: Embryonic stem cell lines derived from human blastocysts. Science 282(5391), 1145-1147 (1998).
3. Murry CE, Keller G: Differentiation of embryonic stem cells to clinically relevant populations: lessons from embryonic development. Cell 132(4), 661-680 (2008).
4. Crook J, Peura T, Kravets L, et al.: The generation of six clinical-grade human embryonic stem cell lines. Cell Stem Cell 1(5), 490-494 (2007).
5. Zarzeczny A, Caulfield T: Emerging ethical, legal and social issues associated with stem cell research and the current role of the moral status of the embryo. Stem Cell Rev. 5(2), 96-101 (2009).
6. Rao M, Condic ML: Alternative sources of pluripotent stem cells: scientific solutions to an ethical dilemma. Stem Cells Dev. 17(1), 1-10 (2008).
7. Hanna J, Wernig M, Markoulaki S, et al.: Treatment of sickle cell anemia mouse model with iPS cells generated from autologous skin. Science 318(5858), 1920-1923 (2007).
8. Kazuki Y, Hiratsuka M, Takiguchi M, et al.: Complete genetic correction of iPS cells from duchenne muscular dystrophy. Mol. Ther. 18(2), 386-393 (2009).
9. Condic ML, Rao M: Regulatory issues for personalized pluripotent cells. Stem Cells 26(11), 2753-2758 (2008).
10. Carpenter MK, Frey-Vasconcells J, Rao MS: Developing safe therapies from human pluripotent stem cells. Nat. Biotechnol. 27(7), 606-613 (2009).
11. Hentze H, Graichen R, Colman A: Cell therapy and the safety of embryonic stem cell-derived grafts. Trends Biotechnol. 25(1), 24-32 (2007).
12. Preti RA: Bringing safe and effective cell therapies to the bedside. Nat. Biotechnol. 23(7), 801-804 (2005).
13. Yu J, Vodyanik MA, Smuga-Otto K, et al.: Induced pluripotent stem cell lines derived from human somatic cells. Science 318(5858), 1917-1920 (2007).
14. Takahashi K, Tanabe K, Ohnuki M, et al.: Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 131(5), 861-872 (2007).
15. Aasen T, Raya A, Barrero MJ, et al.: Efficient and rapid generation of induced pluripotent stem cells from human keratinocytes. Nat. Biotechnol. 26(11), 1276-1284 (2008).
16. Loh YH, Agarwal S, Park IH, et al.: Generation of induced pluripotent stem cells from human blood. Blood 113(22), 5476-5479 (2009).
17. Lee TH, Song SH, Kim KL, et al.: Functional recapitulation of smooth muscle cells via induced pluripotent stem cells from human aortic smooth muscle cells. Circ. Res. 106(1), 120-128 (2010).
18. Sun N, Panetta NJ, Gupta DM, et al.: Feeder-free derivation of induced pluripotent stem cells from adult human adipose stem cells. Proc. Natl Acad. Sci. USA 106(37), 15720-15725 (2009).
19. Giorgetti A, Montserrat N, Aasen T, et al.: Generation of induced pluripotent stem cells from human cord blood using OCT4 and SOX2. Cell Stem Cell 5(4), 353-357 (2009).
20. Aoi T, Yae K, Nakagawa M, et al.: Generation of pluripotent stem cells from adult mouse liver and stomach cells. Science 321(5889), 699-702 (2008).
21. Eminli S, Foudi A, Stadtfeld M, et al.: Differentiation stage determines potential of hematopoietic cells for reprogramming into induced pluripotent stem cells. Nat. Genet. 41(9), 968-976 (2009).
22. Kim JB, Zaehres H, Wu G, et al.: Pluripotent stem cells induced from adult neural stem cells by reprogramming with two factors. Nature 454(7204), 646-650 (2008).
23. Lin T, Ambasudhan R, Yuan X, et al.: A chemical platform for improved induction of human iPSCs. Nat. Methods 6(11), 805-808 (2009).
24. Chin MH, Mason MJ, Xie W, et al.: Induced pluripotent stem cells and embryonic stem cells are distinguished by gene expression signatures. Cell Stem Cell 5(1), 111-123 (2009).
25. Maherali N, Hochedlinger K: Guidelines and techniques for the generation of induced pluripotent stem cells. Cell Stem Cell 3(6), 595-605 (2008).
26. Jaenisch R, Young R: Stem cells, the molecular circuitry of pluripotency and nuclear reprogramming. Cell 132(4), 567-582 (2008).
27. Takahashi K, Yamanaka S: Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 126(4), 663-676 (2006).
28. Hacein-Bey-Abina S, Garrigue A, Wang GP, et al.: Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1. J. Clin. Invest. 118(9), 3132-3142 (2008).
29. Okita K, Ichisaka T, Yamanaka S: Generation of germline-competent induced pluripotent stem cells. Nature 448(7151), 313-317 (2007).
30. Kaji K, Norrby K, Paca A, Mileikovsky M, Mohseni P, Woltjen K: Virus-free induction of pluripotency and subsequent excision of reprogramming factors. Nature 458(7239), 771-775 (2009).
31. Okita K, Nakagawa M, Hyenjong H, Ichisaka T, Yamanaka S: Generation of mouse induced pluripotent stem cells without viral vectors. Science 322(5903), 949-953 (2008).
32. Yu J, Hu K, Smuga-Otto K, et al.: Human induced pluripotent stem cells free of vector and transgene sequences. Science 324(5928), 797-801 (2009).
33. Woltjen K, Michael IP, Mohseni P, et al.: piggyBac transposition reprograms fibroblasts to induced pluripotent stem cells. Nature 458(7239), 766-770 (2009).
34. Soldner F, Hockemeyer D, Beard C, et al.: Parkinsons disease patient-derived induced pluripotent stem cells free of viral reprogramming factors. Cell 136(5), 964-977 (2009).
35. Zhou H, Wu S, Joo JY, et al.: Generation of induced pluripotent stem cells using recombinant proteins. Cell Stem Cell 4(5), 381-384 (2009).
36. Kim D, Kim CH, Moon JI, et al.: Generation of human induced pluripotent stem cells by direct delivery of reprogramming proteins. Cell Stem Cell 4(6), 472-476 (2009).
37. Brimble SN, Zeng X, Weiler DA, et al.: Karyotypic stability, genotyping, differentiation, feeder-free maintenance, and gene expression sampling in three human embryonic stem cell lines derived prior to August 9, 2001. Stem Cells Dev. 13(6), 585-597 (2004).
38. Draper JS, Smith K, Gokhale P, et al.: Recurrent gain of chromosomes 17q and 12 in cultures human embryonic stem cells. Nat. Biotechnol. 22(1), 53-54 (2004).
39. Rosler ES, Fisk GJ, Ares X, et al.: Long-term culture of human embryonic stem cells in feeder-free conditions. Dev. Dyn. 229(2), 259-274 (2004).
40. Blum B, Benvenisty N: The tumorigenicity of diploid and aneuploid human pluripotent stem cells. Cell Cycle 8(23), 3822-3830 (2009).
41. Doi A, Park IH, Wen B, et al. Differential methylation of tissue- and cancer-specific CpG island shores distinguishes human induced pluripotent stem cells, embryonic stem cells and fibroblasts. Nat. Genet. 41(12), 1350-1353 (2009).
42. Muller FJ, Laurent LC, Kostka D, et al.: Regulatory networks define phenotypic classes of human stem cell lines. Nature 455(7211), 401-405 (2008).
43. Hentze H, Soong PL, Wang ST, Phillips BW, Putti TC, Dunn NR: Teratoma formation by human embryonic stem cells: evaluation of essential parameters for future safety studies. Stem Cell Res. (2009) (Epub ahead of print).
44. Rao M: Tumorigenesis and embryonic stem cell-derived therapy. Stem Cells Dev. 16(6), 903-904 (2007).
45. Cooke MJ, Stojkovic M, Przyborski SA: Growth of teratomas derived from human pluripotent stem cells is influenced by the graft site. Stem Cells Dev. 15(2), 254-259 (2006).
46. Shih CC, Forman SJ, Chu P, Slovak M: Human embryonic stem cells are prone to generate primitive, undifferentiated tumors in engrafted human fetal tissues in severe combined immunodeficient mice. Stem Cells Dev. 16(6), 893-902 (2007).
47. Lee AS, Tang C, Cao F, et al.: Effects of cell number on teratoma formation by human embryonic stem cells. Cell Cycle 8(16), 2608-2612 (2009).
48. Miura K, Okada Y, Aoi T, et al.: Variation in the safety of induced pluripotent stem cell lines. Nat. Biotechnol. 27(8), 743-745 (2009).
49. Osafune K, Caron L, Borowiak M, et al.: Marked differences in differentiation propensity among human embryonic stem cell lines. Nat. Biotechnol. 26(3), 313-315 (2008).
50. Howe SJ, Mansour MR, Schwarzwaelder K, et al.: Insertional mutagenesis combined with acquired somatic mutations caused leukemogenesis following gene therapy in SCID-X1 patients. J. Clin. Invest. 118(9), 3143-3150 (2008).
51. WiCell Research Institute www.wicell.org